AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06694844 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket preservation with M1
Description: Following extraction, socket will be filled with the combination of bovine xenograft and autograft and then covered with d-PTFE M1 membrane (peramem membrane).
Study NCT06694844 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket preservation with M2
Description: Following extraction, socket will be filled with the combination of bovine xenograft and autograft and then covered with d-PTFE M2 membrane (Cytoplast membrane).
Study NCT05362799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozol (Femara, Novartis)
Description: Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days.
Study NCT05362799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozol (Femara, Novartis) combined with Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt)
Description: Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
Study NCT05362799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland)
Description: Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry.
Study NCT05362799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) combined with metformin
Description: Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
Study NCT05704049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Investigational medicinal product; Pharmaceutical form: Solution for Subcutaneous administration; Route of administration: Subcutaneous
Study NCT06089707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone Nasal Spray
Description: IN naloxone will be administered to participants, after which a single dose of buprenorphine will be given to participants
Study NCT05318066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer Lactate and Norepinephrine infusion
Description: Arm Fluids (FL)- 500 mL of ringer lactate over 10 minute prior to the administration of procedural medications.~Arm Vasopressor (VP)- Patients in this group would receive norepinephrine infusion at a dose of 0.08 μg/kg/min over 10 minutes prior and 5 minutes after tracheal intubation.
Study NCT05704049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Investigational medicinal product; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
Study NCT05704049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Tablet; Route of administration: Oral
Study NCT05704049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone IV
Description: Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous
Study NCT05704049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Background Treatment; ATC code: R03DC03; Pharmaceutical form: As per local commercial product; Route of administration: Oral
Study NCT05704049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Background Treatment; ATC code: N02BE01; Pharmaceutical form: As per local commercial product; Route of administration: Oral or intravenous (IV)
Study NCT05605574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance Care Planning conversations
Description: In the first conversation, patients and caregivers are guided through conversations using a modified version of the Serious Illness Conversation Guide, which explores understanding of the AYA's illness and treatment plan, information preferences, goals, sources of support, fears and worries, and goals of care. In the second conversation, participants are introduced to and encouraged to complete portions of the advance care planning document, Voicing My CHOiCES. Participants are guided through a discussion of this experience and may share their perceptions of each other's preferences for care. In the third conversation, participants may discuss previous conversations or other new Advance Care Planning topics. At the end of each conversation, a summary of the conversation will be documented in the electronic medical record and the investigator will communicate directly any information requested by the patient or caregiver to be shared with specific members of the patient's care team.
Study NCT05704049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Background Treatment; ATC code: R06AA02; Pharmaceutical form: As per local commercial product; Route of administration: Oral or IV
Study NCT05704049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Background Treatment/Rescue medication; ATC code: H02AB04; Pharmaceutical form: As per local commercial product; Route of administration: IV
Study NCT04974125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drain
Description: A 10 mm suction drain is placed through a trocar in the right hypochondrium (liver).
Study NCT04974125 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual exsufflation
Description: Exsufflation through the trocar opening.
Study NCT06346535 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive Testing
Description: Digital Cognitive Testing performed at home.
Study NCT06448390 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: The patients are randomized to either walking 30 minutes 3 times a week or lifting the body to a tip toe position three times a day until pain in the claves and then add another five liftings before ending the session
Study NCT06554496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP Treatment
Description: Continuous Positive Airway Pressure (CPAP) therapy will be administered to patients for 3 months. The CPAP device will be set to deliver a continuous flow of air at a prescribed pressure to keep the patient's airway open during sleep.
Study NCT06434805 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sex workers and sexual minorities education workshop
Description: The participants will receive a one-day workshop (four sessions). The generic content aims at enhancing the understanding of sexual orientation, gender identities, social stigma, sex work and sexual orientation and human rights (session 1), the lived experience of SWSM (session 2), the content specifically related to the medical and healthcare field, including be familiar with the professional and ethical obligations (session 3), the skills that can be adopted when providing services to SWSM (session 4).
Study NCT04790968 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA-PET
Description: Prostate specific membrane antigen positron emission tomography
Study NCT04790968 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA-PET/MRI
Description: Prostate specific membrane antigen positron emission tomography combined with magnetic resonance imaging
Study NCT04790968 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA-PET/CT
Description: Prostate specific membrane antigen positron emission tomography combined with computed tomography imaging
Study NCT05405166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isatuximab IV
Description: Pharmaceutical form: Concentrate solution for IV infusion; Route of administration: Intravenous
Study NCT05405166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SC
Description: Pharmaceutical form: Solution for subcutaneous administration; Route of administration: Subcutaneous (SC)
Study NCT05405166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study NCT05405166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study NCT05405166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pharmaceutical form: hard capsules; Route of administration: Oral
Study NCT05405166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pharmaceutical form: hard capsules; Route of administration: Oral
Study NCT05405166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Pharmaceutical form: As per local commercial product; Route of administration: Oral; Auxiliary Medicinal Product (AxMP) i.e., background treatment; ATC code: H02AB02
Study NCT05405166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: As per local commercial product; Route of administration: Oral; Auxiliary Medicinal Product (AxMP) i.e., background treatment; ATC code: H02AB02
Study NCT05405166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: R03DC03
Study NCT05405166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: R03DC03
Study NCT05405166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol / Acetaminophen
Description: Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: N02BE01
Study NCT05405166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol / Acetaminophen
Description: Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: N02BE01
Study NCT05405166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Pharmaceutical form: As per local commercial product; Route of administration: As premedication- oral; for management of infusion reactions-IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: R06AA02
Study NCT05405166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Pharmaceutical form: As per local commercial product; Route of administration: As premedication- oral; for management of infusion reactions-IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: R06AA02
Study NCT05405166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Pharmaceutical form: As per local commercial product; Route of administration: As premedication-IV; for management of infusion reactions- IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: H02AB04
Study NCT05405166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Pharmaceutical form: As per local commercial product; Route of administration: As premedication-IV; for management of infusion reactions- IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: H02AB04
Study NCT05379985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-6236
Description: Oral Tablets
Study NCT04941898 — intervention group
Intervention type: BIOLOGICAL
Intervention: PEGylated Recombinant Factor VIII
Description: Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII)
Study NCT05870007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20 Mg Oral Tablet
Description: Atorvastatin 20mg
Study NCT06274047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given by PO
Study NCT06274047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: Given by PO
Study NCT06582641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Group Connection - Middle School (PGC-MS)
Description: Peer Group Connection - Middle School (PGC-MS) is the treatment condition. PGC-MS is a school-based positive youth development program for students entering the transition year into middle school (6th or 7th grade). PGC-MS aims to improve school engagement and social-emotional learning skills that support adolescent health and educational outcomes for program participants. Participants receive 45-minute outreach sessions held 3 to 4 times per month for the full school year. Schools are expected to implement a minimum of 18 outreach sessions over the school year. PGC-MS outreach sessions are delivered by older peer leaders (8th, 9th, or 10th graders) who are carefully selected by faculty advisors and trained on how to deliver program content.
Study NCT06160440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC1011
Description: Each subject in the SAD groups participated in 1 treatment period only and reside at the clinical research unit (CRU) from Day -1 (the day before dosing) to Day 7 (144 hours post dose).
Study NCT06160440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SC1011
Description: Each subject in the SAD groups participated in 1 treatment period only and reside at the clinical research unit (CRU) from Day -1 (the day before dosing) to Day 7 (144 hours post dose).
Study NCT05165966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dosage of COVID-19 vaccine (Vero cell), Inactivated
Description: High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
Study NCT05165966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated
Description: Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
Study NCT05870007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate 600 Mg Oral Tablet
Description: Sodium bicarbonate would be titrated up to 1800mg per day according to metabolic acidosis severity during clinical follow-up
Study NCT06408831 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Classroom Teaching University Students Intervention Group
Description: Web-based cyber sexual violence training and counseling will be provided to female classroom teaching students, who are the intervention group, and the effect of the intervention on cyber sexual violence experience, sensitivity and cyber security will be examined.
Study NCT04988126 — intervention group
Intervention type: OTHER
Intervention: Interventions
Description: Observational study, not applicable
Study NCT04707183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine IV Infusion
Description: Lidocaine will infused through erector spinae plane block catheter in patients with traumatic rib fracture.
Study NCT04707183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine via ESPB
Description: 10 ml of 2% lidocaine will be infused through ESPB in treatment group
Study NCT01179997 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interventricular pacing delay optimization by using Tissue Doppler-derived displacement curves
Study NCT01179997 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocardiographic optimization of the interventricular pacing delay according to QRS width
Study NCT06425978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellular Matrix / A-CP-HA Kit
Description: For infiltration, a prior preparation of the region with anesthetic cream is performed, procaine 25 mg/g + lidocaine 25 mg/g (Emla 5% cream) in the vulvar area and vaginal introitus. Occlusion of the area with plastic film is performed for 20 minutes. After asepsis and antisepsis, infiltration is performed with mesotherapy needles 31G 4mm, using the technique of superficial point-to-point mesotherapy microinjections, in the vestibule and the first 3 cm of the posterior wall of the vagina.
Study NCT06425978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local estrogen therapy (Blissel, estriol 50 micrograms/g vaginal gel)
Description: Blissel®, Estriol vaginal gel 50 micrograms/g, daily application for 15-21 days in a row, then two times a week for 24 weeks (6 months). Application instructions will be explained to the patients. The gel should be applied in the vagina using an applicator with the marked dose, the full applicator should be inserted into the vagina and emptied, preferably at night.
Study NCT06068725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training videos
Description: After determining the application and control groups in the research, the purpose of the research was explained to both groups. The mobile phone usage skills of the individuals who will be included in the application group were evaluated with the Digital Literacy Scale. Training videos for 15 people each (30 minutes in total) regarding symptom management were shared on the phones of the patients/relatives in the application groups, and the patients and their relatives were informed and watched the training video. Data collection forms would be filled out before the application (Z0), on the 30th day of the application (Z1), and on the 90th day of the application (Z2).
Study NCT05440955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: left fronto-temporal transcranial Direct Current Stimulation (tDCS)
Description: The study intervention consists of ten 20-minutes sessions of active or sham tDCS. Sessions will be delivered twice daily and separated by at least 2 hours for 5 consecutive weekdays. The electric current will be generated by an electric stimulator (class IIa medical device). During the entire tDCS session, the subject is at rest, comfortably seated in a chair in a quiet room. A clinician will be present for the entire session duration. The current will be applied via a pair of rubber electrodes (35 cm²) placed on the surface of the scalp. The anode will be placed over the left dorsolateral prefrontal cortex. The cathode will be placed over the left auditory cortex. The stimulation parameters will be set at 2-mA for 20 minutes, with a progressive increase during the first 30-sec and a progressive decrease during the last 30-sec of each session. The impedance of the applied current is monitored by the stimulator during each session.
Study NCT05440955 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: left fronto-temporal transcranial Direct Current Stimulation (tDCS)
Description: The study intervention consists of ten 20-minutes sessions of active or sham tDCS. Sessions will be delivered twice daily and separated by at least 2 hours for 5 consecutive weekdays. The electric current will be generated by an electric stimulator (class IIa medical device). During the entire tDCS session, the subject is at rest, comfortably seated in a chair in a quiet room. A clinician will be present for the entire session duration. The current will be applied via a pair of rubber electrodes (35 cm²) placed on the surface of the scalp. The anode will be placed over the left dorsolateral prefrontal cortex. The cathode will be placed over the left auditory cortex. The stimulation parameters will be set at 2-mA for 20 minutes, with a progressive increase during the first 30-sec and a progressive decrease during the last 30-sec of each session. The impedance of the applied current is monitored by the stimulator during each session.
Study NCT05582577 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection with subthreshold micropulse laser
Description: Group A: intravitreal interjection of Bevacizumab and subthreshold micropulse laser
Study NCT05582577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab injection alone
Description: Group B: Intravitreal injection of Bevacizumab alone
Study NCT05799144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA Vaccine
Description: Given pBI-11 IM
Study NCT05799144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus Tumor Antigen Vaccine
Description: Given into a muscle
Study NCT05799144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given into vein
Study NCT05799144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: Undergo a CT
Study NCT05799144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo an MRI
Study NCT05799144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo blood sample collection
Study NCT05799144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy